Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Quality of Life and Neuropsychiatric Disorders in Patients With Graves’ Orbitopathy: Current Concepts
source: Autoimmunity Reviews
year: 2018
authors: Bruscolini A, Sacchetti M, La Cava M, Nebbioso M, Iannitelli A, Quartini A, Lambiase A, Ralli M, de Virgilio A, Greco A
summary/abstract:Graves’ disease (GD) is an autoimmune chronic thyroiditis frequently associated with development of Graves’ orbitopathy (GO) characterized by proptosis, strabismus, impairment of visual function, ocular surface inflammation and dry eye. As consequence, patients with GO experience impairment of quality of life and social function and could develop a neurobehavioral syndrome, ranging from anxious to depressive or psychotic disorders.
To date, the pathogenic mechanism underlying neuropsychiatric disorders in patients with GD has not been clearly understood. In fact, the development of neuropsychiatric disorders in patients with GO has been associated with both the detrimental effects of the altered circulating thyroid hormones on the nervous system, and with the psychological discomfort caused by poor quality of life, reduced social interactions and relapsing course of the disease.
This paper summarizes current evidence on neuropsychiatric abnormalities in Graves’ disease focusing on its impact on QoL and psychosocial function. We remark the importance of a multidisciplinary approach and we emphasize the potential benefit of neuropsychiatric approach on disease perception, patient compliance to medical and/or surgical treatment and clinical outcomes.
organization: University Sapienza of Rome, Italy; University of l'Aquila, Italy; A. Fiorini Hospital, ItalyDOI: 10.1016/j.autrev.2017.12.012
read more
myBinderRelated Content
-
Type 2 Diabetic Patients With Graves’ Disease Have More Frequent and Severe Graves’ OrbitopathyBackground and Aims: Due to the worldwi...
-
Open Letter to HusbandsDear Husband of Graves’, This letter i...
-
U.S. Department of Education’s Individuals with Disabilities Act (IDEA)The Individuals with Disabilities Educat...
-
Thyroid Eye Disease Drug Meets Primary Endpoint for Proptosis ReductionTop-line results from the OPTIC trial sh...
-
“TED Today” Episode 4https://www.facebook.com/ThyroidEyes/vid...
-
Efficacy and Safety of Mycophenolate Mofetil in Patients With Active Moderate-to-Severe Graves’ OrbitopathyContext: Graves' orbitopathy (GO) is a ...
-
Patient Story – Thyroid Eye Diseasehttps://www.youtube.com/watch?v=GnXbXSah...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google